Royalty Pharma (RPRX) Non-Current Debt (2019 - 2026)
Royalty Pharma (RPRX) posted Non-Current Debt of $9.0 billion for Q1 2026, little changed sequentially from $9.0 billion in Q4 2025, and up 35.32% YoY from $6.6 billion in Q1 2025.
Royalty Pharma (RPRX) Non-Current Debt (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Non-Current Debt for 8 years, with the latest figure at $9.0 billion in Q1 2026.
- Quarterly Non-Current Debt rose 35.32% year-over-year to $9.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 billion (up 35.32% YoY) and the FY2025 annual result came in at $9.0 billion, up 17.58% from the prior year.
- Non-Current Debt was little changed at $9.0 billion in Q1 2026 per RPRX's latest filing, from $9.0 billion in the prior quarter.
- Over five years, Non-Current Debt peaked at $9.0 billion in Q1 2026 and troughed at $6.1 billion in Q4 2022.
- A 5-year average of $7.1 billion and a median of $7.1 billion in 2022 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2024 and 2026: Non-Current Debt dropped 13.79% in 2024, then soared 35.32% in 2026.
- Over 5 years, Non-Current Debt stood at $6.1 billion in 2022, then advanced by 0.27% to $6.1 billion in 2023, then gained by 24.08% to $7.6 billion in 2024, then increased by 17.58% to $9.0 billion in 2025, then increased by 0.06% to $9.0 billion in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $9.0 billion, $9.0 billion, and $8.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.96 Bn |
| Mar 31, 2026 | 8.96 Bn |
| Dec 31, 2025 | 8.95 Bn |
| Sep 30, 2025 | 8.57 Bn |
| Jun 30, 2025 | 7.00 Bn |
| Mar 31, 2025 | 6.62 Bn |
| Dec 31, 2024 | 7.61 Bn |
| Sep 30, 2024 | 6.61 Bn |
| Jun 30, 2024 | 7.60 Bn |
| Mar 31, 2024 | 6.14 Bn |
| Dec 31, 2023 | 6.14 Bn |
| Sep 30, 2023 | 6.13 Bn |
| Jun 30, 2023 | 6.13 Bn |
| Mar 31, 2023 | 7.12 Bn |
| Dec 31, 2022 | 6.12 Bn |
| Sep 30, 2022 | 7.11 Bn |
| Jun 30, 2022 | 7.11 Bn |
| Mar 31, 2022 | 7.10 Bn |
| Dec 31, 2021 | 7.10 Bn |
| Sep 30, 2021 | 7.09 Bn |